Dr. John Cush RheumNow
4 years 7 months ago
Retrospective study of 98 patients with X-linked agammaglobulinemia (XLA) shows arthritis seen in 46% - more oligo- than polyarthritis, affecting . Knee, hip, and ankle. IVIG response rates around 70%; many w/ arthritis had missense mutation https://t.co/lreW5hkyr9
Dr. John Cush RheumNow
4 years 7 months ago
Voriconazole-induced synovitis, enthesitis and periostitis described in woman treated for invasive aspergillosis. She had polyarthralgias, synovitis (MRI and US), and periostitis on xray. Voriconazole prev. caused periostitis; now drug induced arthritis? https://t.co/10MnYvD3sA
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Dr. John Cush RheumNow
4 years 7 months ago
New 2021 JIA guidelines w 55 recommendations, 36 conditional and 19 strong. #RWCS2022 @RWCSmtg Dr Susan Shenoi https://t.co/CMETQeOdch
Dr. John Cush RheumNow
4 years 7 months ago
ACR RISE registry study looked at Rx of 3276 Sarcoidosis pts from 184 rheum practices finds 59.3% rx w/ steroids (24% prolonged steroids). and 12.1 Rx w/ biologics or tsDMARDs, mostly TNFi (inflx). But wide practice-level variations in Rx https://t.co/95CEDai2uN
Dr. John Cush RheumNow
4 years 7 months ago
MMWR study of shows 2 dose mRNA COVID vax during pregnancy was 61% effective preventing infant COVID. Among 176 infants hosp w/ COVID-19, 84% were born to mothers who were not vaccinated during pregnancy.https://t.co/mWgHHcL05u
Dr. John Cush RheumNow
4 years 7 months ago
Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/fdZAFFDrYW
Dr. John Cush RheumNow
4 years 7 months ago
Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in any BMI category.
Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.
Dr. John Cush RheumNow
4 years 7 months ago
We have an exciting agenda for #RNL2022, with topics ranging from Psoriatic Disease for Rheumatologists to Advances in Psoriasis Management and speakers from around the world, including Dr. Bruce Strober.
Register Today!
https://t.co/VZ2hmxAmDw https://t.co/AJbSLNXDql
